425 related articles for article (PubMed ID: 16390601)
1. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
2. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
5. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary toxicity associated with erlotinib.
Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
[TBL] [Abstract][Full Text] [Related]
7. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
8. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Yoneda KY; Shelton DK; Beckett LA; Gandara DR
J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
[TBL] [Abstract][Full Text] [Related]
9. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Shi L; Tang J; Tong L; Liu Z
Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
[TBL] [Abstract][Full Text] [Related]
10. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
12. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
[TBL] [Abstract][Full Text] [Related]
14. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2015 Feb; 27(1):40-51. PubMed ID: 24724908
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
17. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Wu X; Gao G; Ren S; Zhou C
Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib therapy for non-small cell lung cancer.
Birnbaum A; Ready N
Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
20. [Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Ohashi Y; Suzuki K; Sakurai M; Shino M; Murakami H; Takahashi T; Yamamoto N
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1327-31. PubMed ID: 19692772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]